14 October 2021
EMA/773886/2021
Committee for Medicinal Products for Human Use (CHMP)

Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Active substance(s): upadacitinib

Procedure No. EMEA/H/C/PSUSA/00010823/202102

Period covered by the PSUR: 15 August 2020 to 15 February 2021

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for upadacitinib, the scientific conclusions of CHMP are as follows:

In view of available data on diverticulitis from clinical trial and spontaneous reports including cases with a close temporal relationship, a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between upadacitinib and diverticulitis is established. The PRAC concluded that the product information of products containing upadacitinib should be amended accordingly.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for upadacitinib the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing upadacitinib is unchanged subject to the proposed changes to the product information

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.